New medical approaches in advanced ovarian cancer

Giacomo Corrado; Eleonora Palluzzi; Carolina Bottoni; Antonella Pietragalla; Vanda Salutari; Viola Ghizzoni; Mariagrazia Distefano; Giovanni Scambia; Maria Gabriella Ferrandina

doi:10.23736/S0026-4806.19.06139-1

New medical approaches in advanced ovarian cancer

Giacomo Corrado, Eleonora Palluzzi, Carolina Bottoni, Antonella Pietragalla, Vanda Salutari, Viola Ghizzoni, Mariagrazia Distefano, Giovanni Scambia, Maria Gabriella Ferrandina

Research output: Contribution to journal › Article

3 Citations (Scopus)

Abstract

Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynaecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.

Original language	English
Pages (from-to)	N/A-N/A
Journal	Minerva Medica
DOIs	https://doi.org/10.23736/S0026-4806.19.06139-1
Publication status	Published - 2019

Keywords

ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.23736/S0026-4806.19.06139-1

Cite this

@article{0f2a69932e7a4ecaa001606f73c6e5fa,

title = "New medical approaches in advanced ovarian cancer",

abstract = "Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynaecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.",

keywords = "ovarian cancer, ovarian cancer",

author = "Giacomo Corrado and Eleonora Palluzzi and Carolina Bottoni and Antonella Pietragalla and Vanda Salutari and Viola Ghizzoni and Mariagrazia Distefano and Giovanni Scambia and Ferrandina, {Maria Gabriella}",

year = "2019",

doi = "10.23736/S0026-4806.19.06139-1",

language = "English",

pages = "N/A--N/A",

journal = "Minerva Medica",

issn = "0026-4806",

publisher = "Edizioni Minerva Medica:Corso Bramante 83-85, 10126 Turin Italy:011 39 011 678282318, EMAIL: [email protected], INTERNET: http://www.minervamedica.it, Fax: 011 39 011 674502",

}

TY - JOUR

T1 - New medical approaches in advanced ovarian cancer

AU - Corrado, Giacomo

AU - Palluzzi, Eleonora

AU - Bottoni, Carolina

AU - Pietragalla, Antonella

AU - Salutari, Vanda

AU - Ghizzoni, Viola

AU - Distefano, Mariagrazia

AU - Scambia, Giovanni

AU - Ferrandina, Maria Gabriella

PY - 2019

Y1 - 2019

N2 - Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynaecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.

AB - Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynaecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.

KW - ovarian cancer

UR - http://hdl.handle.net/10807/136336

U2 - 10.23736/S0026-4806.19.06139-1

DO - 10.23736/S0026-4806.19.06139-1

M3 - Article

SN - 0026-4806

SP - N/A-N/A

JO - Minerva Medica

JF - Minerva Medica

ER -

New medical approaches in advanced ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this